BC Extra | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

Following the nationwide expansion of China’s pilot program for centralized procurement of generics and off-patent originator drugs, Beijing is adding a second group of 33 drugs and unveiling new rules that could increase the number...
BC Extra | Oct 16, 2019
Company News

AI play Healx raises $56M to repurpose drugs for rare disease

Bolstered by a $56 million series B round, Healx is taking human bias out of drug discovery by leaving most strategic and technical decisions up to AI. Its approach is to use an AI-powered platform...
BC Extra | Jun 28, 2019
Clinical News

June 28 Clinical Quick Takes: Imfinzi extends survival in Phase III SCLC study; plus LSK, Pfizer, FibroGen, Aclaris and more

AZ's Imfinzi shows survival benefit in Phase III for SCLC  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III CASPIAN trial showed Imfinzi plus etoposide and platinum-based chemotherapy met the primary endpoint...
BC Extra | Nov 29, 2018
Preclinical News

Chemputer automates drug synthesis

A University of Glasgow team developed an app-controlled robotic platform that enables the automated chemical synthesis and purification of drugs by including software that converts written chemistry protocols into code that drives production. Manual chemical...
BioCentury | Sep 1, 2018
Politics, Policy & Law

Back to School: A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
BC Extra | Jul 11, 2018
Politics & Policy

Pfizer creates deadline for Trump drug plan

Pfizer Inc. (NYSE:PFE) Chairman and CEO Ian Read has turned President Donald Trump’s fury over drug price increases into an opportunity to create a de facto deadline for the Trump administration to implement its drug...
BC Extra | Jul 9, 2018
Company News

Trump blasts Pfizer for price hikes, threatens to respond

President Donald Trump threatened to take action against companies for increasing drug prices in a tweet Monday that specifically named Pfizer Inc. (NYSE:PFE). Trump tweeted, “Pfizer & others should be ashamed that they have raised...
BioCentury | Oct 24, 2016
Strategy

Lilly’s history lesson

  Eli Lilly and Co. President and CEO-in-waiting David Ricks will inherit a well-stocked pipeline, seven drugs less than three years old and a much-improved growth trajectory. To maintain momentum, he’ll have to execute on...
BC Week In Review | Sep 26, 2016
Company News

NuSirt Biopharma, OWL deal

The companies partnered to develop diagnostic tools for trials of NuSirt’s Phase II candidate NS-0200 in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The product is a fixed-dose combination of leucine, metformin and...
BC Innovations | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Endothelial cell nitric oxide synthase 3 (NOS3; eNOS)

Genitourinary disease INDICATION: Genitourinary Patient sample and mouse studies suggest promoting NOS3 activity with Viagra sildenafil could help prevent preeclampsia. In patient placental tissue samples or vascular endothelium from a mouse model of preeclampsia, markers...
Items per page:
1 - 10 of 211